Scotiabank analyst George Farmer initiated coverage of NewAmsterdam Pharma with an Outperform rating and $35 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NAMS:
- NewAmsterdam Pharma doses first patient in Phase 3 TANDEM trial
- NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
- NewAmsterdam Pharma Updates Investor Presentation Online
- NewAmsterdam Pharma price target raised to $31 from $25 at RBC Capital
- NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update